CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter's five force analysis
3.5.Government Regulations
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population

3.6.2.Restraints

3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug Exploitation
3.6.2.3.Patent expiration of prescription drugs

3.6.3.Opportunities

3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies

3.7.COVID-19 Impact Analysis for Pain Management Drugs

CHAPTER 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Anticonvulsant

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antimigraine Drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Antidepressant drugs

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.7.4.Tramadol
4.7.5.Hydrocodone
4.7.6.Oxycodone
4.7.7.Others

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

CHAPTER 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic Pain

5.2.1.Market size and forecast, by region
5.2.1.Market analysis, by country

5.3.Neuropathic pain

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Cancer Pain

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Chronic Pain

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Post-operative pain

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Migraine

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Fibromyalgia

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

CHAPTER 6:PAIN MANAGEMENT DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Pain Management Drugs Market, by country

6.2.2.1.U.S. Pain Management Drugs Market, by drug class
6.2.2.2.U.S Pain Management Drugs Market, by indications
6.2.2.3.Canada Pain Management Drugs Market, by drug class
6.2.2.4.Canada Pain Management Drugs Market, by indication
6.2.2.5.Mexico Pain Management Drugs Market, by product
6.2.2.6.Mexico Pain Management Drugs Market, by indication

6.2.3.North America Pain Management Drugs Market, by drug class
6.2.4.North America Pain Management Drugs Market, by indication

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Pain Management Drugs Market, by country

6.3.2.1.UK Pain Management Drugs Market, by drug class
6.3.2.2.UK Pain Management Drugs Market, by indication
6.3.2.3.Germany Pain Management Drugs Market, by drug class
6.3.2.4.Germany Pain Management Drugs Market, by indication
6.3.2.5.France Pain Management Drugs Market, by drug class
6.3.2.6.France Pain Management Drugs Market, by indication
6.3.2.7.Italy Pain Management Drugs Market, by drug class
6.3.2.8.Italy Pain Management Drugs Market, by indication
6.3.2.9.Spain Pain Management Drugs Market, by drug class
6.3.2.10.Spain Pain Management Drugs Market, by indication
6.3.2.11.Rest of Europe Pain Management Drugs Market, by drug class
6.3.2.12.Rest of Europe Pain Management Drugs Market, by indication

6.3.3.Europe Pain Management Drugs Market, by drug Class
6.3.4.Europe Pain Management Drugs Market, by indication

6.4.Asia Pacific
6.5.Key market trends, growth factors, and opportunities

6.5.1.Asia-Pacific Pain Management Drugs Market, by country

6.5.1.1.Japan pain management drugs market, by drug class
6.5.1.2.Japan pain management drugs market, by indications
6.5.1.3.China pain management drugs market, by drug class
6.5.1.4.China Pain Management Drugs Market, by indication
6.5.1.5.Australia Pain Management Drugs Market, by drug class
6.5.1.6.Australia Pain Management Drugs Market, by indication
6.5.1.7.India Pain Management Drugs Market, by drug class
6.5.1.8.India Pain Management Drugs Market, by indication
6.5.1.9.South Korea Pain Management Drugs Market, by drug class
6.5.1.10.South Korea Pain Management Drugs Market, by indication
6.5.1.11.Taiwan Pain Management Drugs Market, by drug class
6.5.1.12.Taiwan Pain Management Drugs Market, by indication
6.5.1.13.Rest of Asia-Pacific Pain Management Drugs Market, by drug class
6.5.1.14.Rest of Asia-Pacific Pain Management Drugs Market, by indication

6.5.2.Asia-Pacific Pain Management Drugs Market, by drug Class
6.5.3.Asia-Pacific Pain Management Drugs Market, by indication

6.6.LAMEA

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.LAMEA Pain Management Drugs Market, by country

6.6.2.1.Brazil Pain Management Drugs Market, by drug class
6.6.2.2.Brazil Pain Management Drugs Market, by indication
6.6.2.3.Saudi Arabia Pain Management Drugs Market, by drug class
6.6.2.4.Saudi Arabia Pain Management Drugs Market, by indication
6.6.2.5.South Africa Pain Management Drugs Market, by drug class
6.6.2.6.South Africa Pain Management Drugs Market, by indication
6.6.2.7.Rest of LAMEA Pain Management Drugs Market, by drug class
6.6.2.8.Rest of LAMEA Pain Management Drugs Market, by indication

6.6.3.LAMEA Pain Management Drugs Market, by drug Class
6.6.4.LAMEA Pain Management Drugs Market, by indication

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.ELI LILY AND COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.

7.4.GLAXOSMITHKLINE PLC (GSK)

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments

7.5.JOHNSON & JOHNSON

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.MERCK & CO., INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.MYLAN N.V.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.NOVARTIS INTERNATIONAL AG

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.PFIZER INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PURDUE PHARMA L.P.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments